Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24933032 | 0.83 | MAPT (0.52) | KMT2AALDH1A1MAPTMAPK1MEN1 | |
| SCHEMBL7931690 | 0.83 | CYP2C9 (0.60) | KMT2AALDH1A1MAPTMAPK1MEN1 | |
| SCHEMBL17996498 | 0.81 | TSHR (0.47) | KMT2AALDH1A1MAPTMEN1GAA | |
| SCHEMBL2329778 | 0.80 | KDM4E (0.46) | KMT2AALDH1A1MAPTMAPK1MEN1 | |
| SCHEMBL2073759 | 0.79 | TDP1 (0.54) | ALDH1A1MAPTMAPK1GAATDP1 | |
| SCHEMBL11563229 | 0.79 | PTGS1 (0.50) | TSHRCYP2C9APPLMNA | |
| SCHEMBL6012036 | 0.79 | SCN4A (0.49) | ALDH1A1MAPTMAPK1TSHRCYP2C9 | |
| SCHEMBL13218297 | 0.79 | TSHR (0.43) | KMT2AMEN1TDP1TSHRCYP2C9 | |
| SCHEMBL8969482 | 0.79 | CYP2C9 (0.56) | KMT2AALDH1A1MAPTMAPK1MEN1 | |
| SCHEMBL940075 | 0.78 | MAPT (0.54) | KMT2AALDH1A1MAPTMAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0357348-B1 | Process for preparing p-bromophenoxyacetaldehyde dialkylacetal derivatives | UBE INDUSTRIES (JP) | 1994-06-08 | — | — | EP | claimed |
| EP-0357348-A2 | Process for preparing p-bromophenoxyacetaldehyde dialkylacetal derivatives | UBE INDUSTRIES, LTD. (JP) | 1990-03-07 | — | — | EP | claimed |
| US-20220388964-A1 | (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | HIBERCELL, INC. | 2022-12-08 | — | — | US | disclosed |
| WO-2020210828-A1 | (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | HIBERCELL, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| US-20120295915-A1 | AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-11-22 | — | — | US | disclosed |
| EP-2503890-A1 | AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline LLC (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011066211-A1 | AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-06-03 | — | — | WO | disclosed |
| EP-1214306-A1 | LIQUID CRYSTAL COMPOUNDS | Qinetiq Limited (GB) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001021606-A1 | LIQUID CRYSTAL COMPOUNDS | QINETIQ LIMITED (GB) | 2001-03-29 | — | — | WO | disclosed |
| EP-0357348-B1 | Process for preparing p-bromophenoxyacetaldehyde dialkylacetal derivatives | UBE INDUSTRIES (JP) | 1994-06-08 | — | — | EP | disclosed |
| US-4982008-A | Process for preparing p-bromophenoxyacetaldehyde dialkylacetal compounds | UBE INDUSTRIES, LTD. (JP) | 1991-01-01 | — | — | US | disclosed |
| EP-0357348-A2 | Process for preparing p-bromophenoxyacetaldehyde dialkylacetal derivatives | UBE INDUSTRIES, LTD. (JP) | 1990-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295915-A1 | AZABENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, COASY | KMT2A 1044/4885ALDH1A1 187/4885MAPT 4781/4885 |
| US-20220388964-A1 | (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | EIF2AK4, GCN1, GNAI2 | KMT2A 1119/4885ALDH1A1 1814/4885MAPT 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.